- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02455011
Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of REMD-477 in Subjects With Type 2 Diabetes Mellitus
April 9, 2018 updated by: REMD Biotherapeutics, Inc.
A Randomized, Placebo-controlled, Double-blind, Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Single and Repeated Subcutaneous (SC) Doses of REMD-477 in Subjects With Type 2 Diabetes Mellitus
This is a randomized, placebo-controlled, double-blind, dose escalation study to evaluate safety, tolerability, PK and PD of single and repeated SC doses of REMD-477 in Type 2 diabetic subjects.
The study will be conducted at multiple sites in the United States and will enroll approximately 102 subjects with Type 2 diabetes who are either treatment-naïve, controlled with diet and exercise or treated with oral antidiabetic medications.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The study will consist of three parts: Part A - Dose Escalation, Part B - Adaptive Dose Cohort, and Part C - REMD-477 in Combination with Metformin.
Part A includes 5 cohorts that will be enrolled and dosed sequentially at escalating doses.
Each cohort will consist of 12 subjects randomized in a 3:1 (active: placebo) fashion.
Part B includes a single dose cohort that will enroll 12 subjects (9 on active treatment and 3 on placebo) with dose level and frequency determined by a Dose Level Review Meeting (DLRM)Committee.
Part C includes 2 cohorts of T2DM patients currently treated with metformin alone, and each cohort will consist of 15 subjects (10 on active treatment and 3 on placebo).
Study Type
Interventional
Enrollment (Actual)
75
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Florida
-
Miami, Florida, United States
-
-
Texas
-
San Antonio, Texas, United States
-
-
Washington
-
Renton, Washington, United States
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Men and women between the ages of 18 and 65 years old, inclusive, at the time of screening;
- Females of non-child bearing potential must be ≥1 year post-menopausal (confirmed by a serum follicle-stimulating hormone (FSH) levels ≥ 40 IU/mL) or documented as being surgically sterile, and females of child bearing potential must use two medically acceptable methods of contraception;
- Male subjects must be willing to use clinically acceptable contraception during treatment and for 2 months after the last administration of REMD-477;
- Normal or clinically-acceptable physical examination, laboratory test values, and 12-lead ECG (reporting heart rate and PR, QRS, QT, and QTcF) at screening;
- Body mass index between 23 and 40 kg/m2, inclusive, at screening;
- Diagnosed with Type 2 diabetes as defined by the current American Diabetes Association (ADA) criteria;
- Subjects in Parts A and B only: Treatment-naive, controlled with diet and exercise, or treated with oral antidiabetic medications and willing to wash-out and discontinue oral medications during the study;
- Fasting plasma glucose 126 - 270 mg/dL (7-15 mM), inclusive, at screening and at re-test on Day -1;
- Subjects in Parts A and B only: Screening HbA1c of 7.0-10 % inclusive for subjects not currently taking any oral antidiabetic medications, or 6.5-9.5% for subjects receiving acceptable oral antidiabetic medications;
- Subjects in Part C only: Screening HbA1c of 7.5-10 % inclusive for subjects on stable doses of metformin.
Exclusion Criteria:
- History of drug or alcohol abuse within the last 6 months or a positive illegal drug urine test result;
- History or family history of pancreatic neuroendocrine tumors or multiple endocrine neoplasia;
- History or family history of pheochromocytoma;
- Known or suspected susceptibility to infectious disease (eg, taking immunosuppressive agents or has a documented inherited or acquired immunodeficiency);
- Positive for human immunodeficiency virus (HIV) antibodies, hepatitis B surface antigen (HbsAg), or hepatitis C antibodies (HepC Ab);
- Participation in an investigational drug or device trial within 30 days of screening or within 5 times the half-life of the investigational agent in the other clinical study, if known, whichever period is longer;
- Blood donor, or blood loss>300 mL, within 30 days of Day 1;
- Recent use (6 weeks prior to Screening) of thiazolidinediones, >half-maximal dose sulfonylurea agent therapy, or any injectable antidiabetic agents (exenatide and other injectable GLP-1 agonists, insulin and insulin analogs, etc.);
- Other gastrointestinal, cardiac, renal and CNS (i.e. hypoglycemia unawareness) conditions specific to diabetes that would pose additional risk to subject's safety or interfere with the study evaluation, procedures or completion;
- Lipid panel profiles of non-HDL-C (total cholesterol minus HDL-C) >219 mg/dL, LDL-C >189 mg/dL, and/or fasting triglycerides >499 mg/dL;
- Female subject is pregnant or breastfeeding.
Other inclusion and exclusion criteria may apply.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: REMD-477 Treatment A
Administered as a single and repeated SC doses in subjects with Type 2 Diabetes
|
|
Placebo Comparator: Matching placebo
Placebo administered as single and repeated SC doses in subjects with Type 2 Diabetes
|
|
Experimental: REMD-477 Treatment B
Administered as a single and repeated SC doses in subjects with Type 2 Diabetes
|
|
Experimental: REMD-477 Treatment C
Administered as a single and repeated SC doses in subjects with Type 2 Diabetes
|
|
Experimental: REMD-477 Treatment D
Administered as a single and repeated SC doses in subjects with Type 2 Diabetes
|
|
Experimental: REMD-477 Treatment E
Administered as a single and repeated SC doses in subjects with Type 2 Diabetes
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of treatment emergent adverse events per subject, including changes in vital signs, physical and neurological examinations, laboratory safety tests and ECGs
Time Frame: 141 Days
|
141 Days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Pharmacokinetic (PK) profile (parameters including maximum observed concentration (Cmax), area under the curve (AUC) serum-concentration, clearance, and half-life (t1/2) after single and repeated SC doses.
Time Frame: 141 Days
|
141 Days
|
Changes in fasting glucose and insulin levels following single and repeated SC doses of REMD-477.
Time Frame: 141 Days
|
141 Days
|
Changes in glucose and insulin AUC following a Mixed Meal Tolerance Test.
Time Frame: Day 29, Day 57 and Day 85
|
Day 29, Day 57 and Day 85
|
Incidence of REMD-477 neutralizing and non-neutralizing antibodies
Time Frame: 141 Days
|
141 Days
|
Incidence of elevated alanine transaminase (ALT) or aspartate transaminase (AST) values >3x the upper limit of normal with concomitant >2x increases in alkaline phosphatase (ALP) and/or >2x total bilirubin.
Time Frame: 141 Days
|
141 Days
|
Incidence and severity of elevated amylase and lipase values at >2.5x ULN after study treatment
Time Frame: 141 Days
|
141 Days
|
Geometric mean ratio to baseline over time of AST, ALT, ALP and total bilirubin.
Time Frame: 141
|
141
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2015
Primary Completion (Actual)
January 1, 2018
Study Completion (Actual)
February 1, 2018
Study Registration Dates
First Submitted
May 20, 2015
First Submitted That Met QC Criteria
May 21, 2015
First Posted (Estimate)
May 27, 2015
Study Record Updates
Last Update Posted (Actual)
April 10, 2018
Last Update Submitted That Met QC Criteria
April 9, 2018
Last Verified
April 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- R477-201
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
Guang NingRecruitingType 2 Diabetes Mellitus | Type1 Diabetes Mellitus | Monogenetic Diabetes | Pancreatogenic Diabetes | Drug-Induced Diabetes Mellitus | Other Forms of Diabetes MellitusChina
-
University of Trás-os-Montes and Alto DouroCompletedType 2 Diabetes Mellitus | Diabetes-Related ComplicationsPortugal
-
Northern Care Alliance NHS Foundation TrustBrighter ABCompletedDiabetes type1 | Diabetes type2United Kingdom
-
VeraLight, Inc.InLight SolutionsUnknownGestational Diabetes | Insulin Dependent Diabetes | Non Insulin Dependent DiabetesUnited States
-
Garvan Institute of Medical ResearchWeizmann Institute of ScienceActive, not recruitingType 2 Diabetes Mellitus | Pre DiabetesAustralia
-
Oregon State UniversitySanofiCompletedType I or Type II Diabetes (Excludes Gestational Diabetes)
-
University of RoehamptonRecruitingType2 Diabetes Mellitus | Pre DiabetesUnited Kingdom
-
Peking Union Medical College HospitalUnknownType 2 Diabetes Mellitus | Type 1 Diabetes Mellitus | Gestational Diabetes Mellitus | Pancreatogenic Diabetes Mellitus | Pregestational Diabetes Mellitus | Diabetes Patients in Perioperative PeriodChina
-
Taichung Veterans General HospitalNational Health Research Institutes, TaiwanRecruitingDiabetes Complications | Type 2 Diabetes | Maturity-Onset Diabetes of the Young (MODY)Taiwan
Clinical Trials on REMD-477
-
REMD Biotherapeutics, Inc.CompletedType1 Diabetes MellitusUnited States
-
REMD Biotherapeutics, Inc.CompletedDiabetes | Type 1 Diabetes MellitusUnited States
-
The University of Texas Health Science Center at...SuspendedType 2 Diabetes | Insulin Sensitivity | Glucose Tolerance ImpairedUnited States
-
Duke UniversityTerminatedHyperglycemia Drug InducedUnited States
-
Duke UniversityTerminatedHyperglycemia Drug InducedUnited States
-
University of California, San DiegoREMD Biotherapeutics, Inc.Completed
-
University of California, San DiegoREMD Biotherapeutics, Inc.Active, not recruiting
-
AbbottAbbott Japan Co.,LtdCompletedSecondary Hyperparathyroidism | Chronic Kidney Disease on HemodialysisJapan
-
University of California, San DiegoJuvenile Diabetes Research Foundation; The Leona M. and Harry B. Helmsley Charitable... and other collaboratorsCompleted
-
Ayman SaadSobi, Inc.Withdrawn